Helmholtz Gemeinschaft


Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC)

[img] PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Item Type:Article
Title:Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC)
Creators Name:Campa, D. and Huesing, A. and Stein, A. and Dostal, L. and Boeing, H. and Pischon, T. and Tjonneland, A. and Roswall, N. and Overvad, K. and Ostergaard, J.N. and Rodriguez, L. and Sala, N. and Sanchez, M.J. and Larranaga, N. and Huerta, J.M. and Barricarte, A. and Khaw, K.T. and Wareham, N. and Travis, R.C. and Allen, N.E. and Lagiou, P. and Trichopoulou, A. and Trichopoulos, D. and Palli, D. and Sieri, S. and Tumino, R. and Sacerdote, C. and van Kranen, H. and Bueno-de-Mesquita, H.B. and Hallmans, G. and Johansson, M. and Romieu, I. and Jenab, M. and Cox, D.G. and Siddiq, A. and Riboli, E. and Canzian, F. and Kaaks, R.
Abstract:The mTOR (mammalian target of rapamycin) signal transduction pathway integrates various signals, regulating ribosome biogenesis and protein synthesis as a function of available energy and amino acids, and assuring an appropriate coupling of cellular proliferation with increases in cell size. In addition, recent evidence has pointed to an interplay between the mTOR and p53 pathways. We investigated the genetic variability of 67 key genes in the mTOR pathway and in genes of the p53 pathway which interact with mTOR. We tested the association of 1,084 tagging SNPs with prostate cancer risk in a study of 815 prostate cancer cases and 1,266 controls nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). We chose the SNPs (n=11) with the strongest association with risk (p<0.01) and sought to replicate their association in an additional series of 838 prostate cancer cases and 943 controls from EPIC. In the joint analysis of first and second phase two SNPs of the PRKCI gene showed an association with risk of prostate cancer (OR(allele)=0.85, 95% CI 0.78-0.94, p=.3x10(-3) for rs546950 and OR(allele)=0.84, 95% CI 0.76-0.93, p=5.6x10(-4) for rs4955720). We confirmed this in a meta-analysis using as replication set the data from the second phase of our study jointly with the first phase of the Cancer Genetic Markers of Susceptibility (CGEMS) project. In conclusion, we found an association with prostate cancer risk for two SNPs belonging to PRKCI, a gene which is frequently overexpressed in various neoplasms, including prostate cancer.
Keywords:Carcinoma, Case-Control Studies, Europe, Genetic Predisposition to Disease, Genetic Variation, Genome-Wide Association Study, Genotype, Isoenzymes, Multicenter Studies as Topic, Neoplasms, Prostatic Neoplasms, Protein Kinase C, Risk Factors, Signal Transduction, TOR Serine-Threonine Kinases
Source:PLoS ONE
Publisher:Public Library of Science
Page Range:e16914
Date:23 February 2011
Official Publication:https://doi.org/10.1371/journal.pone.0016914
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library